Trials / Terminated
TerminatedNCT01141478
Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria
Randomized Controlled Trial of Proton Beam Radiotherapy + Sorafenib vs. Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Loma Linda University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to determine whether proton beam radiotherapy plus Sorafenib compared to Sorafenib alone will produce the best results for treating patients with Hepatocellular Carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Proton Beam Radiotherapy | Fifteen consecutive sessions |
| DRUG | Sorafenib | 400 mg po bid |
Timeline
- Start date
- 2010-09-08
- Primary completion
- 2014-12-26
- Completion
- 2016-06-10
- First posted
- 2010-06-10
- Last updated
- 2021-10-15
- Results posted
- 2021-09-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT01141478. Inclusion in this directory is not an endorsement.